Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review

Yoon, Kyung Hee

doi:10.1155/2010/686480

Cited by 39 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms of action of TAC in LN have not been fully elucidated. In vitro and animal studies have shown that TAC reduces production of interleukin 2 (IL-2) and other cytokines such as tumour necrosis factor α, interferon γ, IL-6 and IL-10 by activated T cells 29. By inhibiting T cell activation, signals for B cell activation, class-switching and immunoglobulin production are indirectly attenuated 30.…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

Ying²,

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

Ying²,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This favorable response observed in these patients of lupus suggested that tacrolimus or cyclosporine at low doses is effective in preventing lupus reactivation 152. Several recent studies have confirmed the beneficial actions of tacrolimus or FK-506, especially in the management of lupus nephritis 153,154…”

Section: Uv Radiation-induced Skin Lesions In Lupus and Mast Cellsmentioning

confidence: 90%

Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation

Das¹

2010

JIR

View full text Add to dashboard Cite

Lupus is a chronic, systemic inflammatory condition in which eicosanoids, cytokines, nitric oxide (NO), a deranged immune system, and genetics play a significant role. Our studies revealed that an imbalance in the pro- and antioxidants and NO and an alteration in the metabolism of essential fatty acids exist in lupus. The current strategy of management includes administration of nonsteroidal anti-inflammatory drugs such as hydroxychloroquine and immunosuppressive drugs such as corticosteroids. Investigational drugs include the following: 1) belimumab, a fully human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, also known as B-cell-activation factor of the TNF family; 2) stem cell transplantation; 3) rituximab, a chimeric monoclonal antibody against CD20, which is primarily found on the surface of B-cells and can therefore destroy B-cells; and 4) IL-27, which has potent anti-inflammatory actions. Our studies showed that a regimen of corticosteroids and cyclophosphamide, and methods designed to enhance endothelial NO synthesis and augment antioxidant defenses, led to induction of long-lasting remission of the disease. These results suggest that methods designed to modulate molecular signatures of the disease process and suppress inflammation could be of significant benefit in lupus. Some of these strategies could be vagal nerve stimulation, glucose–insulin infusion, and administration of lipoxins, resolvins, protectins, and nitrolipids by themselves or their stable synthetic analogs that are known to suppress inflammation and help in the resolution and healing of the inflammation-induced damage. These strategies are likely to be useful not only in lupus but also in other conditions, such as rheumatoid arthritis, scleroderma, ischemia-reperfusion injury to the myocardium, ischemic heart disease, and sepsis.

show abstract

“…Thus, T cell functions are often modulated in the treatment of those autoimmune diseases and in suppression of rejection of transplants [13,14,15,16,17]. Since interleukin 2 (IL-2) is required to initiate and support T cell activation [18], IL-2 and IL-2 signal transduction are favorite target for T cell suppression.…”

Section: Introductionmentioning

confidence: 99%

Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression

et al. 2012

View full text Add to dashboard Cite

Streptavidin is widely used as a detection tool in biology research because of its high affinity and specificity binding to biotin. Biotin-streptavidin system has also been explored for detection of infection and tumor in clinical medicine. Here, we show immunosuppressive property of streptavidin on T cell activation and proliferation. Upon CD3 and CD28 stimulation, CD4+ T cells produce interleukin 2 (IL-2) and express IL-2 receptor α chain (CD25). Addition of streptavidin in T cell culture suppressed IL-2 synthesis and CD25 expression with no cytotoxicity. The immunosuppressive effect of streptavidin was reversed by excessive biotin. Conjugated to a single chain anti-CD7 variable fragment (scFvCD7), streptavidin was directly delivered to T cells and showed substantially more profound suppressive effect on T cell activation. These results suggest that streptavidin could potentially be used as a novel immunomodulator.

show abstract

Efficacy and Cytokine Modulating Effects of Tacrolimus in Systemic Lupus Erythematosus: A Review

Cited by 39 publications

References 31 publications

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation

Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression

Contact Info

Product

Resources

About